Advances in angiogenesis research: Relevance to urological oncology

Journal of Urology

Volumn 158, Issue 5, 1997, Pages 1663-1674

  Campbell, Steven C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Angiogenesis factor; Neovascularization; Urologic neoplasms

Indexed keywords

ANGIOGENIC FACTOR;

ANGIOGENESIS; ARTICLE; BLADDER CANCER; CANCER GROWTH; GROWTH REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TESTIS CANCER; TUMOR VASCULARIZATION; URINARY TRACT CANCER;

EID: 0030763876     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64090-4     Document Type: Review

References (160)

1. Hanahan, D. and Folkman, J.: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353, 1996.
2. Folkman, J., Klagsbrun, M., Sasse, J., Wadzinski, M., Ingber, D. and Vlodavsky, I.: A heparin-binding angiogenic protein -basic fibroblast growth factor - is stored within basement membrane. Amer. J. Path., 130: 393, 1988.
3. Bouck, N., Stellmach, V. and Hsu, S. C.: How tumors become angiogenic. Adv. Cancer Res., 69: 135, 1996.
4. Polverini, P. J.: The pathophysiology of angiogenesis. Crit. Rev. Oral Biol. Med., 6: 230, 1995.
5. Sunderkotter, C., Goebeler, M., Schulze-Osthoff, K., Bhardwaj, R. and Sorg, C.: Macrophage-derived angiogenesis factors. Pharm. Ther., 51: 195, 1991.
6. Hori, K., Suzuki, M., Tanda, S. and Saito, S.: In vivo analysis of tumor vascularization in the rat. Jap. J. Cancer Res., 81: 279, 1990.
7. Dvorak, H. F., Nagy, J. A. and Dvorak, A. M.: Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3: 77, 1991.
8. Folkman, J.: The role of angiogenesis in tumor growth. Cancer Biol., 3: 65, 1992.
9. Folkman, J.: Tumor angiogenesis. In: Molecular Basis of Cancer. Edited by J. Mendelsohn, P. M. Howley, M. A. Israel and L. A. Liotta. Philadelphia, W. B. Saunders Co., pp. 206-232, 1995.
10. Gimbrone, M. A., Jr., Leapman, S. B., Cotran, R. S. and Folkman, J.: Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med., 136: 261, 1972.
11. Hori, A., Sasada, R., Matsutani, E., Naito, K., Sakura, V., Fujita, T. and Kozai, Y.: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res., 51: 6180, 1991.
12. Ueki, N., Nakazato, M., Ohkawa, T., Ikeda, T., Amuro, Y., Hada, T. and Higashino, K.: Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochem. Biophys. Acta, 1137: 189, 1992.
13. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S. and Ferrara, N.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature, 362: 841, 1993.
14. Liotta, L. A., Kleinerman, J. and Saidel, G. M.: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res., 34: 997, 1974.
15. Holmgren, L., O'Reilly, M. S. and Folkman, J.: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med., 1: 149, 1995.
16. O'Reilly, M. S., Holmgren, L., Chen, C. and Folkman, J.: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med., 2: 689, 1996.
17. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R. and Folkman, J.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277, 1997.
18. Weidner, N., Semple, J. P., Welch, W. R. and Folkman, J.: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. New Engl. J. Med., 324: 1, 1991.
19. Macchiarini, P., Fantanini, G., Hardin, M. J., Squartini, F. and Angeletti, C. A.: Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet, 340: 145, 1992.
20. Guidi, A. J., Abu-Jawdeh, G., Berse, B., Jackman, R. W., Tognazzi, K., Dvorak, H. F. and Brown, L. F.: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J. Nat. Cancer Inst., 87: 1237, 1995.
21. Takebayashi, Y., Aklyama, S., Yamada, K., Akiba, S. and Aikou, T.: Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer, 78: 226, 1996.
22. Tanigawa, N., Amaya, H., Matsumura, M., Shimomatsuya, T., Horiuchi, T., Muraoka, R. and Iki, M.: Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res., 56: 2671, 1996.
23. Craft, P. S. and Harris, A. L.: Clinical prognostic significance of tumour angiogenesis. Ann. Oncol., 5: 305, 1994.
24. Zatterstrom, U. K., Brun, E., Willen, R., Kjellen, E. and Wennerberg, J.: Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head and Neck, 17: 312, 1996.
25. Senger, D. R., Van De Water, L., Brown, L. F., Nagg, J. A., Yeo, K. T., Yeo, T. K., Berse, B., Jackson, R. W., Dvorak, A. M. and Dvorak, H. F.: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev., 12: 303, 1993.
26. Rosen, E. M. and Goldberg, I. D.: Scatter factor and angiogenesis. Adv. Cancer Res., 67: 257, 1995.
27. Rooney, P., Kumar, S., Ponting, J. and Wang, M.: The role of hyaluronan in tumour neovascularization. Int. J. Cancer, 60: 632, 1995.
28. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F. and Folkman, J.: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Nat. Cancer Inst., 86: 356, 1994.
29. Singh, R., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N. and Fidler, I. J.: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Nat. Acad. Sci., 92: 4562, 1995.
30. Pesenti, E., Sola, F., Mongelli, N., Grandi, M. and Sprea Fico, F.: Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Brit. J. Cancer, 66: 367, 1992.
31. Volpert, O. V., Tolsma, S. S., Pellerin, S., Feige, J. J., Chen, H., Mosher, D. F. and Bouck, N.: Inhibition of angiogenesis by thrombospondin-1. Biochem. Biophys. Res. Com., 217: 326, 1995.
32. Fotsis, T., Pepper, M., Adlercreutz, H., Fleischman, G., Hase, T., Montesano, R. and Schweigerer, L.: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad. Sci., 90: 2690, 1993.
33. Volpert, O. V., Ward, W. F., Lingen, M. W., Chesler, L., Solt, D. B., Johnson, M. D., Moteni, A., Polverini, P. S. and Bouck, N. P.: Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest., 98: 671, 1996.
34. Gagliardi, A. and Collins, D. C.: Inhibition of angiogenesis by antiestrogens. Cancer Res., 53: 533, 1993.
35. Dameron, K. M., Volpert, O. V., Tainsky, M. A. and Bouck, N.: Control of angiogenesis in fibroblasts by P53 regulation of thromobspondin-1. Science, 265: 1582, 1994.
36. Volpert, O. V., Dameron, K. M. and Bouck, N.: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene, 14: 1495, 1997.
37. Dawson, D. W., Tolsma, S. S., Volpert, O. V., Polverini, P. V. and Bouck, N. P.: Retinoblastoma gene expression alters angiogenic phenotype. Proc. Amer. Assoc. Cancer Res., 36: 88, 1995.
38. Wizigmann-Voos, S., Breier, G., Risau, W. and Plate, K. M.: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res., 55: 1358, 1995.
39. Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Marring-Baren, G. and Maime, D.: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res., 56: 2299, 1996.
40. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T. and Kerbel, R. S.: Mutant ras oncogenes upregulate VEGF, VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55: 4575, 1995.
41. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W. and Folkman, J.: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Amer. J. Path., 143: 401, 1993.
42. Brawer, M. K., Deering, R. E., Brown, M., Preston, S. D. and Bigler, S. A.: Predictors of pathologic stage in prostatic carcinoma: The role of neovascularity. Cancer, 73: 678, 1994.
43. Bostwick, D. G., Wheeler, T. M., Blute, M., Barrett, N. M., Maclennan, G. T., Sebo, T. J., Scardino, P. T., Humphrey, P. A., Hudson, M. A., Fradet, Y., Miller, G. J., Crawford, E. D., Blumstein, B. A., Mahran, H. E. and Miles, B. J.: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology, 48: 47, 1996.
44. Wakui, S., Furusato, M., Itoh, T., Sasaki, H., Akiyama, A., Kinoshita, I., Asano, K., Tokuda, T., Aizuwa, S. and Ushigome, S.: Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study. J. Path., 168: 257, 1992.
45. Fregene, T. A., Khanuja, P. S., Noto, A. C., Gehani, S. K., Van Egmont, E. M., Luz, D. A. and Piento, K. J.: Tumor-associated angiogenesis in prostate cancer. Anticancer Res., 13: 2377, 1993.
46. Vesalainen, S., Lipponen, P., Talia, M., Alhava, E. and Syrjanen, K.: Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma. Anticancer Res., 14: 709, 1994.
47. Nakamoto, T., Chang, C., Li, A. and Chodak, G. W.: Basic fibroblast growth factor in human prostate cancer cells. Cancer Res., 52: 571, 1992.
48. Mansson, E., Adams, P., Kan, M. and McKeenan, W. L.: Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res., 49: 2485, 1989.
49. Gleave, M. E., Hsieh, J. T., von Eschenbach, A. C. and Chung, L. W. K.: Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J. Urol., 147: 1151, 1992.
50. Ikeda, T., Lioubin, M. N. and Marquardt, H.: Human transforming growth factor type beta 2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry, 26: 2406, 1987.
51. Truong, L. D., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T. and Thompson, T. C.: Association of transforming growth factor-beta 1, with prostate cancer: an immunohistochemical study. Hum. Path., 24: 4, 1993.
52. Eastham, J. A., Truong, L. D., Rogers, E., Kattan, M., Flanders, K. C., Scardino, P. T. and Thompson, T. C.: Transforming growth factor-beta 1; comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab. Invest., 73: 628, 1995.
53. Steiner, M. S., Zhou, Z. Z., Tonb, D. C. and Barrak, E. R.: Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology, 135: 2240, 1994.
54. Harper, M. E., Goddard, L., Glynne-Jones, E., Wilson, D. W., Price-Thomas, M., Peeling, W. B. and Griffiths, K.: An immunocytochemical analysis of TGF/alpha expression in benign and malignant prostatic tumors. Prostate, 23: 9, 1993.
55. Cohen, D., Simak, R., Fair, W. R., Melamed, J., Scher, H. I. and Cardon-Cardo, C.: Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. J. Urol., 152: 2120, 1994.
56. Hofer, D. R., Sherwood, E. R., Bromberg, W. D., Mendelsohn, J., Lee, C. and Kozlowski, J. M.: Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res., 51: 2780, 1991.
57. Ware, J. L.: Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev., 12: 287, 1993.
58. Ching, K. Z., Ramsey, E., Pettigrew, N., D'Cunha, R., Jason, M. and Dodd, J. G.: Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Molecular Cellular Biochem., 126: 151, 1993.
59. Sitaras, N. M., Sariban, E., Bravo, M., Pantazis, P. and Antoniades, H. N.: Constitutional production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res., 48: 1930, 1988.
60. Fudge, K., Wang, C. Y. and Stearns, M. E.: Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod. Path., 7: 549, 1994.
61. Humphrey, P. A., Zhu, X., Zarnegar, R., Swanson, P. E., Ratliff, T. L., Vollmer, R. T. and Day, M. L.: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Amer. J. Path., 147: 386, 1995.
62. Pisters, L. L., Troncoso, P., Zhau, H. E., Li, W., von Eschenbach, A. C. and Chung, L. W. K.: c-MET proto-oncogene expression in benign and malignant human prostate tissues. J. Urol., 154: 293, 1995.
63. Lokeshwar, V. B., Lokeshwar, B. L., Pham, H. T. and Block, N. L.: Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res., 56: 651, 1996.
64. Sinha, A. A., Gleason, D. F., Staley, N. A., Wilson, M. J., Sameni, M. and Sloane, B. F.: Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis. Anat. Rec., 241: 353, 1995.
65. Achbarou, A., Kaiser, S., Tremblay, G., Ste.-Marie, L. G., Brodt, P., Goltzman, D. and Rabbini, S. A.: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res., 54: 2372, 1994.
66. Nakashima, J., Tachibana, M., Ueno, M., Baba, S. and Tazaki, H.: Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res., 55: 4881, 1995.
67. Meyer, G. E., Yu, E., Siegal, J. A., Petteway, J. C., Blumenstein, B. A. and Brawer, M. K.: Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer, 76: 2304, 1995.
68. Vukanovic, J. and Isaacs, J. T.: Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res., 55: 3517, 1995.
69. Vukanovic, J. and Isaacs, J. T.: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res., 55: 1499, 1995.
70. Vukanovic, J., Hartley-Asp, B. and Isaacs, J. T.: Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate, 26: 235, 1995.
71. Ichikawa, T., Lamb, J. C., Christensson, P. I., Hartley-Asp, B. and Isaacs, J. T.: The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostate cancers. Cancer Res., 52: 3022, 1992.
72. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K. and Fujita, T.: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res., 53: 5233, 1993.
73. Nguyen, N. M., Lehr, J. E. and Pienta, K. J.: Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res., 13: 2143, 1993.
74. Sarosdy, M. F., Higdon, A. L. and Demoor, C. A.: In vivo antitumor activity of bropirimine against PAIII and Dunning Mat-LyLu rodent prostate cancers. J. Urol., 155: 2085, 1996.
75. Joseph, I. B. J. K., Vukanovic, J. and Isaacs, J. T.: Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res., 56: 3404, 1996.
76. Zimmern, P. E., Laub, D. and Leach, G. E.: Fluorescein angiography of the bladder: Technique and relevance to bladder cancer and interstitial cystitis patients. J. Urol., 154: 62, 1995.
77. Hawke, C. K., Delahunt, B. and Davidson, P. J. T.: The prognostic value of microvessel density in bladder cancer. J. Urol., 155: 690A, abstract 1517, 1996.
78. Bochner, B. H., Cote, R. J., Weidner, N., Groshen, S., Chen, S. C., Skinner, D. G. and Nichols, P. W.: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Nat. Cancer Inst., 87: 1603, 1995.
79. Jaeger, T. M., Weidner, N., Chew, K., Moore, D. M., Kerschmann, R. L., Waldman, F. M. and Carroll, P. R.: Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J. Urol., 154: 69, 1995.
80. Dickinson, A. J., Fox, S. B., Persad, R. H., Hollyer, P. J., Sibley, G. N. and Harris, A. L.: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Brit. J. Urol., 74: 762, 1994.
81. Chopin, D. K., Popov, Z., Hoznek, A., Lefrère, M.-A., Bellot, N. and Abbou, C.: P53 and angiogenesis in invasive bladder cancer. J. Urol., part 2, 155: 690A, abstract 1518, 1996.
82. Babkowski, R. C., Zhang, H., Xia, W. Y., Antelo, M., Katz, R. L., Ng, A., Shakelford, D., Marley, G., Veltri, R. and Dinney, C. P.: Angiogenesis does not have prognostic value in T1 bladder cancer. J. Urol., part 2, 155: 615A, abstract 1215, 1996.
83. Chodak, G. W., Haudenschild, C., Gittes, R. F. and Folkman, J.: Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann. Surg., 192: 762, 1980.
84. Chodak, G. W. and Summerhayes, I.: Detection of angiogenesis activity in malignant bladder tissue and cells. J. Urol., 132: 1032, 1984.
85. Chodak, G. W., Scheiner, C. J. and Zetter, B. R.: Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells. New Engl. J. Med., 305: 869, 1981.
86. Chodak, G. W., Hospelhorn, V., Judge, S. M., Mayforth, R., Koeppen, H. and Susse, J.: Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res., 48: 2083, 1988.
87. Chodak, G. W., Shing, Y., Borge, M., Judge, S. M. and Klagsbrun, M.: Presence of heparin binding growth factor in mouse bladder tumors and urine from mice with bladder cancer. Cancer Res., 46: 5507, 1986.
88. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P. and Folkman, J.: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. Nat. Cancer Inst., 85: 241, 1993.
89. Chopin, D. K., Caruelle, J. P., Columbel, M., Palcy, S., Ravery, V., Caruelle, D., Abbou, C. C. and Barritault, D.: Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J. Urol., 150: 1126, 1993.
90. Ravery, V., Jouanneau, J., Gil Diez, S., Abbou, C. C., Carnelle, J. P., Barritault, D. and Chopin, D. K.: Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol. Res., 20: 211, 1992.
91. O'Brien, T., Cranston, D., Fuggle, S., Bicknell, K. and Harris, H. L.: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res., 55: 510, 1995.
92. Joseph, A., Weiss, G. H., Jin, L., Fuchs, A., Choudhury, S., O'Shaugnessy, P., Goldberg, I. D. and Rosen, E. M.: Expression of scatter factor in human bladder carcinoma. J. Nat. Cancer Inst., 87: 372, 1995.
93. O'Brien, T., Cranston, D., Crew, J., Bicknell, K. and Harris, H.: Two mechanisms of basic fibroblast growth factor induced angiogenesis in bladder cancer. Cancer Res., 57: 136, 1997.
94. O'Brien, T., Cranston, D., Crew, J., Bicknell, K. and Harris, H.: Midkine is expressed in bladder cancer and overexpression correlates with a poor outcome in patients with invasive cancers. J. Urol., part 2, 155: 690A, abstract 1515, 1996.
95. Grossfeld, G. D., Ginsberg, D. A., Stein, J. P., Bochner, B. H., Esrig, D., Groshen, S., Dunn, M., Nichols, P. W., Taylor, C. K., Skinner, D. G. and Cole, R. J.: Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Nat. Cancer Inst., 89: 219, 1997.
96. Eder, I. E., Stenzl, A., Hobisch, A., Cronaur, M. V., Bartsch, G. and Klocker, H.: Transforming growth factors-B1 and B2 in serum and urine from patients with bladder carcinoma. J. Urol., 156: 953, 1996.
97. Osawa, S., Terashima, Y., Watanabe, J., Yoshida, K. and Akimoto, M.: Anti-tumor effect of angiogenesis inhibitor AGM 1470 on rat urinary bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl) nitrosoamine (BBN). J. Urol., 153: 523A, abstract 1178, 1995.
98. Tanaka, Y., Kawamata, H., Fujimoto, K. and Oyasu, R.: Angiogenesis inhibitor TNP-470 supresses tumorigenesis in rat urinary bladder. J. Urol., 157: 683, 1997.
99. Morita, T., Shinohara, N. and Tokue, A.: Antitumor effect of a synthetic analogue of fumagillin on murine renal carcinoma. Brit. J. Urol., 74: 416, 1994.
100. Fujioka, T., Hasegawa, M., Ogiu, K., Matsushita, Y., Sato, M. and Kubo, T.: Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. J. Urol., 155: 1775, 1996.
101. Choi, H. R., Kim, S. C., Moon, W. C. and Moon, I. J.: Inhibition of tumor growth and metastatis of renal cell carcinoma by angiogenesis inhibitor TNP-470. J. Urol., part 2, 153: 402A, abstract 696, 1995.
102. Takahashi, A., Sasaki, H., Kim, S. J., Tobisu, K., Kakizoe, T., Tsukamot, T., Kumamoto, Y., Sugimura, T. and Terada, M.: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res., 54: 4233, 1994.
103. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F. and Senger, D. R.: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Amer. J. Path., 143: 1255, 1993.
104. Gnarra, J. R., Zhou, S., Merril, M. J., Wagner, J. R., Krumm, H., Papavassilou, E., Oldfield, E. H., Klausner, R. D. and Lineham, W. M.: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Nat. Acad. Sci., 93: 10589, 1996.
105. Iliopoulous, O., Levy, A. P., Jiang, C., Kaelin, W. G., Jr. and Goldberg, M. A.: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Cancer Sci., 93: 10585, 1996.
106. Fujimoto, K., Ichimori, Y., Kakizoe, T., Okajima, E., Sakamoto, H., Sugimura, T. and Terada, M.: Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem. Biophys. Res. Comm., 180: 386, 1991.
107. Nanus, D. M., Schmitz-Drager, B. J., Motzer, R. J., Lee, A. C., Vlamis, V., Cordon-Cardo, C., Albino, A. P. and Reuter, V. E.: Expression of basic fibroblast growth factor in primary human renal tumors: Correlation with poor survival. J. Nat. Cancer Inst., 85: 1597, 1993.
108. Singh, R. K., Bucana, C. D., Gutman, M., Fan, D., Wilson, M. R. and Fidler, I. J.: Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Amer. J. Path., 145: 365, 1994.
109. Mydlo, J. H., Michaeli, J., Cordon-Cardo, C., Goldenberg, A. S., Heston, W. D. and Fair, W. R.: Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res., 49: 3407, 1989.
110. Gomella, L. G., Sargent, E. R., Wade, T. P., Anglard, P., Linehan, W. M. and Kasid, A.: Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma. Cancer Res., 49: 6972, 1989.
111. Hise, M. K., Jacobs, S. C., Papadimitriou, J. C. and Drochenberg, C. I.: Transforming growth factor-alpha expression in human renal cell carcinoma. TGF-alpha expression in renal cell carcinoma. Urology, 47: 29, 1996.
112. Olivarez, D., Ulbright, T., De Riese, W., Foster, R., Reister, T., Einhorn, L. and Sledge, G.: Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res., 54: 2800, 1994.
113. Viglietto, G., Romano, A., Maglione, D., Rambaldi, M., Paoletti, I., Lago, C. T., Califano, D., Monaco, C., Mineo, H., Santelli, G., Manzo, G., Botti, G., Chiappetta, G. and Persico, M. G.: Neovascularization in human germ cell tumor correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene, 13: 577, 1996.
114. Folkman, J.: Tumor angiogenesis: therapeutic implications. New Engl. J. Med., 285: 1182, 1971.
115. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H. and Folkman, J.: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell, 79: 315, 1994.
116. Kato, T., Sato, K., Kakinuma, H. and Matsuda, Y.: Enhanced suppression of tumor growth by combination of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) Fumagillol TNP-470 and cytotoxic agents in mice. Cancer Res., 54: 5143, 1994.
117. Teicher, B. A., Sotomayor, E. A. and Huang, Z. D.: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastic disease. Cancer Res., 52: 6702, 1992.
118. Bicknell, R. and Harris, A. L.: Anticancer strategies involving the vasculature: Vascular targeting and the inhibition of angiogenesis. Sem. Cancer Biol., 3: 399, 1992.
119. Marshall, J. L. and Hawkins, M. J.: The clinical experience with antiangiogenic agents. Breast Cancer Res. Treat., 36: 253, 1995.
120. Ezekowitz, R. A., Mulliken, J. B. and Folkman, J.: Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. New Engl. J. Med., 326: 1456, 1992.
121. Lippman, S. M., Kavanaugh, J. J., Paredes-Espinoza, M., Delgadillo-Madrueno, F., Paredes-Casillas, P., Hong, W. K., Holdener, E. and Krakoff, I. H.: 13-Cisretinoic acid and interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J. Nat. Cancer Inst., 84: 241, 1992.
122. Lippman, S. M., Parkinson, D. R., Itri, L. M., Weber, R. S., Schantz, S. P., Ota, D. M., Schusterman, M. A., Krakoff, I. H., Gutterman, J. U. and Hong, W. K.: 13-cis-retinoic acid and Interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J. Nat. Cancer Inst., 84: 235, 1992.
123. Higano, C. S.: Alfa interferon and cis-retinoic acid in combination for the treatment of hormone refractory prostate cancer, preliminary results of an ongoing trial. Proc. ASCO, 15: 243, 1996.
124. Motzer, R. J., Schwartz, L., Law, T. M., Murphy, B. A., Hoffman, A. D., Albino, A. P., Vlamis, V. and Nanus, D. M.: Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J. Clin. Oncol., 13: 1950, 1995.
125. Torti, F. M., Shortliffe, L. D., Williams, R. D., Pitts, W. C., Kempson, R. L., Ross, J. C., Palmer, J., Meyers, F., Ferrari, M. and Hannigan, J.: Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J. Clin. Oncol., 6: 476, 1988.
126. Sarosdy, M. F., Lowe, B. A., Schellhammer, P. F., Lamm, D. L., Graham, S. D., Jr., Grossman, H. B., See, W. A., Peabody, J. O., Moon, T. P., Flanigan, R. C., Crawford, E. D. and Morganoth, J.: Oral bropiramine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology, 48: 21, 1996.
127. Atzpodien, J., Hanninen, E. L., Kerchner, H., Bodenstein, H., Pfreundschuh, M., Rebmann, U., Metzner, B., Illiger, H.-J., Jakse, G., Niesel, T., Scholz, H.-J., Wilhelm, S., Pielmeier, T., Zakrzewski, G., Blum, G., Beier, J., Müller, G.-W., Duensing, S., Anton, P., Allhoff, E., Jonas, U. and Poliwoda, H.: Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol., 13: 497, 1995.
128. Eisenberger, M. A., Sinibaldi, V. J., Reyno, L. M., Sridhara, R., Jodrell, D. I., Zuhowski, E. G., Tkaczvk, K. H., Lowitt, M. H., Hemady, R. K. and Jacobs, S. C.: Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J. Clin. Oncol., 13: 2174, 1995.
129. Peehl, D. M., Wong, S. T. and Stamey, T. A.: Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors. J. Urol., 145: 624, 1991.
130. Stein, C. A., LaRocca, R. V., Thomas, R., McAtee, N. and Myers, C. E.: Suramin: an anticancer drug with a unique mechanism of action. J. Clin. Oncol., 7: 499, 1989.
131. Kim, J. H., Sherwood, E. R., Sutkowski, D. M., Lee, C. and Kozlowski, J. M.: Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. J. Urol., 146: 171, 1991.
132. Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Hu, T., Klein, G. and Cheresh, D. A.: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79: 1157, 1994.
133. Ramakrishnan, S., Olson, T. A., Bautch, V. L. and Mohanrag, D.: Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res., 56: 1324, 1996.
134. Oikawa, T., Hirotani, K., Ogasawara, H., Katayana, T., Ashino-Fuse, H., Shimanura, M., Iwaguchi, T. and Nakamura, O.: Inhibition of angiogenesis by bleomycin and its copper complex. Chem. Pharm. Bulletin, 38: 1790, 1990.
135. Hirata, S., Matsubara, T., Saura, R., Tateishi, H. and Hirohata, K.: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheumat, 32: 1065, 1989.
136. Ingber, D. and Folkman, J.: Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest., 59: 44, 1988.
137. Burt, H. M., Jackson, J. K., Bains, S. K., Liggins, R. T., Oktaba, A. M., Arsenault, A. L. and Hunter, W. L.: Controlled delivery of taxol from microspheres composed of a blend of ethylenevinyl acetate copolymer and poly (d,1-lactic acid). Cancer Lett., 88: 73, 1995.
138. Fajardo, L. F., Prionas, S. D., Kowalski, J. and Kwan, H. H.: Hyperthermia inhibits angiogenesis. Rad. Res., 114: 297, 1988.
139. Milas, L., Hunter, N., Furuta, Y., Nishiguchi, I. and Runkel, S.: Antitumour effects of indomethacin alone and in combination with radiotherapy: role of inhibition of tumour angiogenesis. Int. J. Rad. Biol., 60: 65, 1991.
140. Vukanovic, J., Passaniti, A., Hirata, T., Traystman, R. J., Hartley-Asp, B. and Isaacs, J. T.: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res., 53: 1833, 1993.
141. Kusaka, M., Sudo, K., Fujita, T., Marui, S., Itoh, F., Ingber, D. and Folkman, J.: Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Comm., 174: 1070, 1991.
142. Tamargo, R. J., Bok, R. A. and Brem, H.: Angiogenesis inhibition by minocycline. Cancer Res., 51: 672, 1991.
143. Stein, C. A.: Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res., 53: 2239, 1993.
144. Sakamoto, N., Iwahana, M., Tanaka, N. G. and Osada, Y.: Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res., 51: 903, 1991.
145. Homandberg, G. A., Williams, J. E., Grant, D., Schumacher, B. and Eisenstein, R.: Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Amer. J. Path., 120: 327, 1985.
146. Clapp, C., Martial, J. A., Guzman, R. C., Rentier-Deluse, F. and Weiner, R. I.: The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology, 133: 1292, 1993.
147. Moses, M. A., Sudhalter, J. and Langer, R.: Identification of an inhibitor of neovascularization from cartilage. Science, 248: 1408, 1990.
148. Min, H. Y., Doyle, L. V., Vitt, C. R., Zandonella, C. L., Stratton-Thomas, J. R., Shuman, M. A. and Rosenberg, S.: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res., 56: 2428, 1996.
149. Sidky, Y. A. and Borden, E. C.: Inhibition of angiogenesis by interferons: Effects of tumor- and lymphocyte-induced vascular responses. Cancer Res., 47: 5155, 1987.
150. Rastinejad, F., Polverini, P. J. and Bouck, N. P.: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell, 56: 345, 1989.
151. Good, D. J., Polverini, P. J., Rastinejad, F., LeBeau, M. M., Lemons, R. S., Frazier, W. A. and Bouck, W. P.: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Nat. Acad. Sci., 87: 6624, 1990.
152. Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S. I., Carson, H. F. and Sharpe, R. J.: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science, 247: 77, 1990.
153. Cozzolino, F., Torcia, M., Aldinucci, D., Ziche, M., Almerigogna, F., Bani, D. and Stern, D. M.: Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc. Nat. Acad. Sci., 87: 6487, 1990.
154. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J. and Folkman, J.: Inhibition of angiogenesis in vivo by interleukin 12. J. Nat. Cancer Inst., 87: 581, 1995.
155. Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Mahuswari, S., Kleinman, H. K., Reaman, G. H. and Tosato, G.: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med., 182: 155, 1995.
156. Peterson, H. I.: Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. Anticancer Res., 6: 251, 1986.
157. D'Amato, R. J., Loughnan, M. S., Flynn, E. and Folkman, J.: Thalidomide is an inhibitor of angiogenesis. Proc. Nat. Acad. Sci., 91: 4082, 1994.
158. Oikawa, T., Hirotani, K., Ogasawara, H., Katayana, T., Nakamura, O., Iwaguchi, T. and Hiragun, A.: Inhibition of angiogenesis by vitamin D3 analogues. Eur. J. Pharm., 178: 247, 1990.
159. Stewart, R. J. and Folkman, J.: Vascular endothelial growth factor is regulated by androgens in hormone-responsive human prostate carcinoma. J. Urol., part 2, 157: 4, abstract 15; 1997.
160. Ferrer, F. A., Miller, L. J., Andrawis, R. I., Kurtzman, S. H., Albertsen, P. C., Laudone, V. P. and Kreutzer, D. L.: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol., 157: 2329, 1997.